Scaling AI in Pharmaceuticals and Healthcare: From Molecules to Enterprise Transformation

• Generative AI in Medicinal Chemistry: Companies like Lundbeck are using generative models to create virtual small molecules, leveraging past data to predict new candidates with improved properties.
• Biologics and Protein Structure: AI-based predictions are allowing researchers to understand the 3D architecture of complex molecules like antibodies early in the biotherapeutic discovery process.
• Major Industry Event: AI LIVE: The London Summit will gather over 2,000 global leaders under the theme "Technology + Human Purpose" to discuss enterprise AI transformation.
• Breakthrough Discoveries: Anthropic’s Claude model recently identified a previously unknown enzyme system in bacteriophage DNA, potentially representing a new gene-editing mechanism.
• Strategic Leadership: Key speakers include Markus Kede (Lundbeck), Tom Diethe (AstraZeneca), and Matea Deliu (NHS), who are driving the shift from AI experimentation to tangible enterprise impact.

One of the most remarkable applications of AI in drug discovery lies within medicinal chemistry. According to insights shared by Lundbeck, computers can now generate virtual small molecules that serve as inspiration for scientists deciding which compounds to synthesize. These virtual molecules are designed with specific properties in mind, presenting the potential to become the next promising drug candidates.

The AI machinery learns from both past successes and failures, digesting information on the measured properties of molecules already created to predict new virtual structures. This data-driven approach enables the generation of innovative ideas for molecules that exhibit improved properties. By harnessing these capabilities, researchers can move beyond traditional trial-and-error methods, accelerating the identification of viable drug candidates.

This topic will be explored in depth at the upcoming London summit, which will examine how AI is revolutionizing pharmaceutical research and development. The event aims to show how technology is not only accelerating scientific discovery but also improving clinical trial success rates and optimizing drug development pipelines.

AI's impact extends far beyond small molecules; it is currently revolutionizing the realm of biologics, which involve the study of large, complex molecules such as antibodies. Lundbeck highlights that AI-based protein structure predictions are changing the game. These tools allow researchers to understand the intricate architecture of the 3D structure of these molecules early in the biotherapeutic discovery phase, significantly reducing the time required for initial analysis.

Advancements across life sciences and healthcare have been rapid on the frontier side. For instance, Anthropic CEO Dario Amodei recently announced that Claude, their AI model, led the discovery of a molecular machine that "suspects" could represent a new gene-editing mechanism. The AI lab explained that Claude discovered a previously unknown enzyme system hidden in the DNA of bacteriophages.

Beside the enzyme’s gene sits a long array of repeating DNA—a structure that looks somewhat similar to CRISPR. While its precise function, biotechnological utility, or level of significance is not yet clear, the discovery represents a significant leap forward. Dario Amodei noted on X that the work was done mostly by Claude: the life sciences team suggested a broad area of research, Claude read through the literature and genome data to discover something interesting, proposed experiments to verify the discovery, and the team carried them out.

Several industry experts will explore these topics in depth at the summit. Their work illustrates the shift from isolated AI projects to comprehensive enterprise strategies.

Markus Kede, Chief AI Officer at Lundbeck, is responsible for setting the company’s enterprise AI direction and turning rapidly evolving AI capabilities into meaningful impact for patients and the business. He emphasizes that becoming a "bionic company" isn't just about adopting technology; it’s about fusing AI, supercomputing, and human neuroscience to compress discovery timelines from years to months. Kede leads the enterprise AI strategy and transformation agenda, focused on embedding AI and bionic capabilities across the business to drive innovation, accelerate growth, improve productivity, and create measurable value for patients, colleagues, and stakeholders.

Tom Diethe, Executive Director and Head of the Centre for AI at AstraZeneca, leads a department of AI scientists and engineers working across multiple teams. His work spans target discovery, antibody design, in-silico lead optimization, biomarker discovery, clinical trial optimization, and agentic AI for the full drug development pipeline. With over 20 years of experience in applying ML and AI to solve tough problems with social impact, Diethe notes that AI is moving fast to revolutionize drug discovery.

Matea Deliu, Chief Clinical Information Officer at Bromley Healthcare and Guy's & St. Thomas's NHS Foundation Trust, holds executive and senior clinical roles across NHS and commercial organizations. She leads digital strategy, clinical safety governance, and data-led decision-making across community services. At NHS South East London ICB, she leads digital delivery and GP IT strategy for primary care, shaping procurement decisions, responsible AI adoption, and clinical system architecture. As the Primary Care Lead for the Responsible AI UK Health and Social Care Group, she helps shape national policy on AI governance in healthcare.

AI LIVE: The London Summit lands at Olympia on October 20–21, promising to be the essential AI event of 2026. Built for C-suite executives, AI strategists, and senior innovators, the summit focuses on how AI moves from ambition to execution across the enterprise. Attendees will gain practical, decision-ready insights into the technologies, frameworks, and governance models defining the next era of AI.

Across two days, the agenda features:

1. 50+ Expert Speakers: Sharing real-world use cases and strategic direction.
2. 10 Focused Content Themes: Covering generative AI, automation, governance, digital identity, and enterprise transformation.
3. Four Executive-Level Workshops: Designed for hands-on learning and peer discussion.
4. Immersive AI Experience: A dedicated environment showing live demonstrations, interactive installations, and applied AI in action.

This is where strategy meets reality, giving attendees a clear view of how AI is already reshaping industries. The event brings together more than 2,000 global leaders under the theme "Technology + Human Purpose," offering a platform to discuss how biopharma is moving from AI experimentation to true enterprise transformation.